Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pfizer Adjuvanted RSV Vaccine in Older Adults
NCT03572062Phase 2Terminated
- Sponsor
- Pfizer
- Start
- Jun 2018
- Primary completion
- Jun 2020
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 2
01
Overview
A Phase 2 trial of RSVpreF vaccine in respiratory syncytial virus infection (RSV), sponsored by Pfizer. Started Jun 2018; status: terminated.
02
Drugs
RSVpreF vaccine
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT03572062.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03572062.